Department of Experimental and Applied Medicine, Section of Cardiovascular Diseases, University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy.
Heart Fail Rev. 2012 Mar;17(2):291-303. doi: 10.1007/s10741-011-9253-3.
Most patients with heart failure (HF) already have or develop renal dysfunction; this might contribute to their poor outcome. Current treatment for HF can also contribute to worsen renal function. High furosemide doses are traditionally associated with worsening renal function (WRF), but patients with fluid overload may benefit of aggressive fluid removal. Unfortunately, promising therapies like vasopressin antagonists and adenosine antagonists have not been demonstrated to improve outcomes. Likewise, correction of low renal blood flow through dopamine, inotropic agents, or vasodilators does not seem to be associated with a clear benefit. However, transient WRF associated with acute HF treatment may not necessarily portend a poor prognosis. In this review, we focus on the strategies to detect renal dysfunction in acute HF, the underlying pathophysiological mechanisms, and the potential treatments.
大多数心力衰竭(HF)患者已经或发展为肾功能障碍;这可能导致他们的预后不良。HF 的当前治疗也可能导致肾功能恶化。传统上,高剂量呋塞米与肾功能恶化(WRF)相关,但有液体超负荷的患者可能受益于积极的液体清除。不幸的是,像血管加压素拮抗剂和腺苷拮抗剂这样有前途的治疗方法并没有被证明能改善预后。同样,通过多巴胺、正性肌力药或血管扩张剂纠正低肾血流量似乎也没有明显的益处。然而,与急性 HF 治疗相关的短暂性 WRF 不一定预示预后不良。在这篇综述中,我们重点关注急性 HF 中检测肾功能障碍的策略、潜在的病理生理机制和潜在的治疗方法。